1-3 of 3
Michelle Kuhne
Close
Sort by
Journal Articles

Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination

Aldo M Roccaro, MD PhD, Antonio Sacco, BS, Michele Moschetta, MD, Yuji Mishima, PhD, Patricia Maiso, PhD, Daisy Huynh, MPS, Marco Chiarini, MSc, Pina M. Cardarelli, PhD, Lewis Cohen, MD MS, Michelle Kuhne, PhD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 4709.
https://doi.org/10.1182/blood.V124.21.4709.4709
Published: 2014
Journal Articles

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

Aldo M. Roccaro, Antonio Sacco, Cristina Jimenez, Patricia Maiso, Michele Moschetta, Yuji Mishima, Yosra Aljawai, Ilyas Sahin, Michelle Kuhne, Pina Cardarelli, Lewis Cohen, Jesus F. San Miguel, Ramon Garcia-Sanz, Irene M. Ghobrial
Journal: Blood
Blood (2014) 123 (26): 4120–4131.
https://doi.org/10.1182/blood-2014-03-564583
Published: 2014
Includes: Supplemental data
Journal Articles

The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma

Aldo M Roccaro, MD, PhD, Antonio Sacco, BS, Michelle Kuhne, PhD, AbdelKareem Azab, PhD, Patricia Maiso, PhD, Yong Zhang, PhD, Yang Liu, PhD, Feda Azab, BPharm, Ghayas C Issa, MD, Phong Quang, BS, Hai T Ngo, BS, Chin Pan, Ph.D., Lew Choen, PhD, Pina M Cardarelli, Ph.D., Irene M. Ghobrial, MD
Journal: Blood
Blood (2011) 118 (21): 1844.
https://doi.org/10.1182/blood.V118.21.1844.1844
Published: 2011